SHAREHOLDERS' DEFICIT

6 Months Ended

Dec. 31, 2023

Stockholders' Equity Note [Abstract]

SHAREHOLDERS' DEFICIT:

Stock-Based Employee Compensation:

During the three and six months ended December 31, 2023, the Company granted restricted stock units as follows:


	Three Months Ended December 31, 2023	Six Months Ended December 31, 2023

Restricted stock units (RSUs)	—	12,970

The RSUs granted during the six months ended December 31, 2023, vest in equal amounts over a three-year period subsequent to the grant date.

Total compensation cost for stock-based payment arrangements totaling $0.3 and $0.6 million for the three months ended December 31, 2023 and 2022, respectively, and $0.9 and $1.1 million for the six months ended December 31, 2023 and 2022, respectively, was recorded within general and administrative on the unaudited Condensed Consolidated Statements of Operations.

Share Issuance Program:

In fiscal year 2021, the Company filed a $150.0 million shelf registration statement and $50.0 million prospectus supplement with the Securities and Exchange Commission (SEC) under which it may offer and sell, from time to time, up to $50.0 million worth of its Class A common stock in "at-the-market" offerings. During the three and six months ended December 31, 2023 and 2022, the Company did not issue any shares under this prospectus. As of December 31, 2023, $11.6 million remains under the prospectus supplement, which equates to 1.2 million shares based on the Company's share price as of December 31, 2023. The program expires on February 10, 2024.